Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease

Published:2023-02 Issue: Volume:242 Page:108330
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Solomon Joshua,Festa Maria Carolina,Chatzizisis Yiannis S.,Samanta Ratna,Suri Rita S.,Mavrakanas Thomas A.

Funder

Fonds de recherche du Québec Santé

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference97 articles.

1. Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease;Aart-van der Beek;Clinical Pharmacokinetics,2021

2. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus;Alba;Current Medical Research and Opinion,2016

3. Empagliflozin in heart failure with a preserved ejection fraction;Anker;The New England Journal of Medicine,2021

4. Effects of Canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m(2): Subgroup analysis of the randomized CREDENCE trial;Bakris;Clinical Journal of the American Society of Nephrology,2020

5. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial;Barnett;The Lancet Diabetes and Endocrinology,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiological functions of glucose transporter-2: From cell physiology to links with diabetes mellitus;Heliyon;2024-02

2. Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension;Diabetes, Metabolic Syndrome and Obesity;2024-01

3. Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest;Intensive Care Medicine Experimental;2023-11-15

4. Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies;Current Heart Failure Reports;2023-09-02

5. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review;Kidney and Blood Pressure Research;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3